# US 2011/0300105 A1 · Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300105 A1
- Document ID: US20110300105A1
- Status: Published application
- Kind: A1
- Application number: 13/178,092
- Filed: 2011-07-07
- Published: 2011-12-08
- Earliest claimed: 2005-04-06
- Assignees: IBC Pharmaceuticals, Inc.
- Inventors: Chien-Hsing Chang; David M. Goldenberg; William J. McBride; Edmund A. Rossi
- Web page: https://patentgrep.com/patent/US20110300105A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/38: of the suprarenal hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/005: {constructed by phage libraries}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.

## Claims

### Claim 1

A method of treating cancer, a viral infection or an autoimmune disease comprising:
a) obtaining a PEGylated interferon-α (IFN-α) or interferon-β (IFN-β) complex comprising;
i) a PEG (polyethylene glycol) moiety covalently attached to a first peptide;
ii) a fusion protein comprising or IFN-β and a second peptide; and
b) administering the PEGylated IFN-α or IFN-β complex to a subject with cancer, a viral infection or autoimmune disease;
wherein two copies of the second peptide form a dimer that binds to the first peptide to form a PEGylated complex, wherein the amino acid sequence of the second peptide is selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and the amino acid sequence of the first peptide is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

### Claim 2 (depends on 1)

The method of claim 1, wherein the second peptide is attached to the C-terminal end of IFN-α or IFN-β.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IFN-α is IFN-α2b.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first peptide is selected from the group consisting of:
IMP350
(SEQ ID NO: 21)
CGQIEYLAKQIVDNAIQQAGC(SS-tbu)-NH2;
IMP360
(SEQ ID NO: 22)
CGQIEYLAKQIVDNAIQQAGC(SS-tbu)-G-EDANS;
IMP362
(SEQ ID NO: 22)
PEG20 k-CO-CGQIEYLAKQIVDNAIQQAGCG-NH-(CH2)2-EDANS;
IMP413
(SEQ ID NO: 22)
mPEG30 K-CGQIEYLAKQIVDNAIQQAGCG-NH-(CH2)2-EDANS;
IMP421
(SEQ ID NO: 22)
Ac-C-PEG3-C(SStBu)GQIEYLAKQIVDNAIQQAGCG-NH2
and
IMP457
(SEQ ID NO: 22)
Ac-C(mPEG2-Suc 40 K)-PEG3-CGQIEYLAKQIVDNAIQQAGCG-
NH2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the PEGylated complex has a higher anti-viral specific activity than PEGINTRON® (Peginterferon alfa-2b) and PEGASYS® (Peginterferon alfa-2a).

### Claim 6 (depends on 1)

The method of claim 1, wherein the PEGylated complex has a higher anti-proliferative effect on cancer cells in vitro than Peginterferon alfa-2b.

### Claim 7 (depends on 1)

The method of claim 1, wherein the clearance rate of the PEGylated complex from serum is at least an order of magnitude slower than the clearance rate of the unPEGylated IFN-α.

### Claim 8 (depends on 1)

The method of claim 1, wherein the PEGylated complex has greater anti-tumor efficacy in vivo than Peginterferon alfa-2b.

### Claim 9 (depends on 1)

The method of claim 1, wherein the PEG moiety is capped at one end with a methoxy group.

### Claim 10 (depends on 1)

The method of claim 1, wherein the viral infection is hepatitis B, hepatitis C, dengue virus, influenza virus, rhinovirus, cytomegalovirus, herpes simplex, vaccinia virus or encephalomyocarditis virus.

### Claim 11 (depends on 1)

The method of claim 1, wherein the autoimmune disease is multiple sclerosis.
